Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Salesforce Inc (CRM) vs Tilray Brands Inc (TLRY) Price & Performance

Salesforce IncTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Salesforce Inc vs Tilray Brands Inc — how do they compare? Salesforce Inc trades at $228.9 (market cap $187.48B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Salesforce Inc is far larger — about 353.4× Tilray Brands Inc's market cap, and Salesforce Inc pays a 0.77% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Tilray Brands Inc for 31 Days on average.

CRMTLRY
Market Cap
$187.48B$530.54M
Volume
6,155,8229,099,075
Sector
TechnologyHealth
52-Week High
$266.23$21.00
52-Week Low
$150.12$3.57
Typical Hold Time
89 Days31 Days
Enterprise Value
$217.82B$684.46M
Dividend Yield
0.77%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Salesforce Inc

Salesforce (CRM) trades at $229.13, up 2.04% today, showing strong fundamental performance with consistent earnings beats and robust revenue growth. The company maintains exceptional profitability with 77.28% gross margins and 21.99% net income margins. Technical indicators show a bearish trend with the stock trading near resistance at $230, while analyst consensus remains strongly bullish with a $271.91 price target representing 19% upside potential.

CRM presents a compelling investment opportunity with strong AI monetization growth and improving profitability, though facing near-term technical headwinds and software sector volatility. The stock trades at reasonable valuations (P/E 20.86) with solid cash flow generation, but investors should monitor competitive pressures and macroeconomic impacts on enterprise software spending.

Tilray Brands Inc

Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.

The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRM
74% Buy26% Sell
Avg holding period · 89 Days
TLRY
54% Buy46% Sell
Avg holding period · 31 Days

Top news

Latest headlines on both assets

About Salesforce Inc

Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.

Read more on CRM →

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY →